Kuur is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of T cells, called natural killer T cells (NKT cells) and innovative chimeric antigen receptor (CAR) construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors.
Location: United States, Texas, Houston
Employees: 51-200
Founded date: 2006